古泉 英貴 (コイズミ ヒデキ)

Koizumi Hideki

写真a

職名

教授

科研費研究者番号

20551500

現在の所属組織 【 表示 / 非表示

  • 専任   琉球大学   医学研究科   教授  

取得学位 【 表示 / 非表示

  • 京都府立医科大学 -  博士(医学)  医学

職歴 【 表示 / 非表示

  • 2012年06月
     
     

      京都府立医科大学大学院  

  • 2012年07月
    -
    2016年09月

      東京女子医科大学  

  • 2016年10月
    -
    2017年09月

      東京女子医科大学  

  • 2017年10月
    -
    継続中

      琉球大学大学院  

所属学会・委員会 【 表示 / 非表示

  • 2020年04月
    -
    継続中
     

    日本眼循環学会   理事

  • 2021年04月
    -
    継続中
     

    日本眼科学会   評議員

  • 2021年04月
    -
    継続中
     

    日本網膜硝子体学会   理事

研究キーワード 【 表示 / 非表示

  • 画像診断

  • 眼循環

  • 眼科学

  • 網膜硝子体

  • 黄斑

研究分野 【 表示 / 非表示

  • ライフサイエンス / 眼科学

論文 【 表示 / 非表示

  • Retrospective exploratory analyses on gender differences in determinants for incidence and progression of diabetic retinopathy in Japanese patients with type 2 diabetes mellitus.

    Nakayama Y, Yamaguchi S, Shinzato Y, Okamoto S, Millman JF, Yamashiro K, Takemoto N, Uema T, Arakaki K, Higa M, Koizumi H, Shimabukuro M, Masuzaki H

    Endocrine journal ( 一般社団法人 日本内分泌学会 )  68 ( 6 ) 655 - 669   2021年06月

    掲載種別: 研究論文(学術雑誌)

     概要を見る

    <p>Gender differences in risks for macrovascular complications in type 2 diabetes mellitus (T2DM) have been well established. However, the impact of gender differences on diabetic retinopathy (DR) has not been fully elucidated. We therefore retrospectively explored gender-specific determinants for DR in patients with T2DM in a small sized Japanese cohort in Okinawa. There were 214 patients who were diagnosed as no DR (<i>n</i> = 142) and non-proliferative DR (<i>n</i> = 72) in 2009. During the follow-up of median 7 years, 41/142 of incidence, 26/72 of progression, and 67/214 of incidence and progression were observed, respectively. DR was assessed using the modified international clinical DR severity scales. The risks for incidence, progression as well as incidence and progression of DR were comparable between men and women, respectively. Cox proportional hazard models in multivariate analyses demonstrated that the only common determinant in both men and women for DR was the duration of T2DM. Regarding gender-specific determinants, lower level of serum albumin in men as well as higher HbA1c, lower level of estimated glomerular filtration rate, and lower level of serum uric acid in women were extracted, respectively. Although precise mechanisms for such gender-specific determinants of DR still remain unsolved, the present study would highlight a couple of factors associated with gender-specific determinants for DR in a limited numbers of Japanese cohort. Prospective observational studies on gender-specific determinants of DR in a large scale cohort are warranted to further clarify underlying mechanisms.</p>

  • Short axial length and hyperopic refractive error are risk factors of central serous chorioretinopathy.

    Terao N, Koizumi H, Kojima K, Kusada N, Nagata K, Yamagishi T, Yoneda K, Yoshii K, Kinoshita S, Sotozono C

    The British journal of ophthalmology ( British Journal of Ophthalmology )  104 ( 9 ) 1260 - 1265   2020年09月 [ 査読有り ]

    掲載種別: 研究論文(学術雑誌)

     概要を見る

    BACKGROUND/AIMS: To evaluate the axial length (AL) and refractive status in central serous chorioretinopathy (CSC). METHODS: This retrospective observational case series involved 140 patients with CSC (180 eyes) and 78 age-matched and gender-matched control subjects. A detailed ophthalmic examination was performed, including an interferometer measurement of AL. Multimodal imaging comprised colour fundus photography, fluorescein angiography, indocyanine green angiography, fundus autofluorescence photography and spectral domain optical coherence tomography. RESULTS: Eighty eyes of 40 patients were categorised into the bilateral-CSC (b-CSC) group and 100 eyes of 100 patients were categorised into the unilateral-CSC (u-CSC) group. AL of the b-CSC (23.19 mm) and u-CSC (23.75 mm) groups was significantly shorter than that of the control (24.85 mm) group (p<0.001 for both). Moreover, AL was significantly shorter in the b-CSC group than in the u-CSC group (p=0.020). Spherical equivalent (SE) in the b-CSC (0.25 D) group was significantly greater than in the u-CSC (-0.81 D) and control (-1.38 D) groups (p<0.001 for both). Gender (male; OR 4.55; 95% CI 1.13 to 18.40; p=0.033), AL (OR 0.38; 95% CI 0.23 to 0.63; p<0.001), area of choroidal vascular hyperpermeability (OR 1.08; 95% CI 1.03 to 1.13; p=0.002) and presence of descending tract (OR 7.22; 95% CI 1.86 to 28.00; p=0.004) were the variables found to be significantly associated with b-CSC via multiple regression analyses. CONCLUSION: Anatomical features, such as shorter AL and greater SE, may be associated with the pathogenesis of CSC.

  • Two-Year Outcomes of Treat-and-Extend Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration: A Prospective Study.

    Maruko I, Ogasawara M, Yamamoto A, Itagaki K, Hasegawa T, Arakawa H, Nakayama M, Koizumi H, Okada AA, Sekiryu T, Iida T

    Ophthalmology. Retina ( Ophthalmology Retina )  4 ( 8 ) 767 - 776   2020年08月 [ 査読有り ]

    掲載種別: 研究論文(学術雑誌)

     概要を見る

    PURPOSE: To report the 2-year outcomes of intravitreal aflibercept injections (IAIs) in Japanese patients with neovascular age-related macular degeneration (AMD) using a 1-month adjusted treat-and-extend (TAE) regimen. DESIGN: Multicenter, prospective, nonrandomized, interventional study. PARTICIPANTS: Ninety-seven eyes of 97 patients with treatment-naive AMD were studied at 3 tertiary ophthalmological institutions. METHODS: The patients were treated with 3 consecutive monthly IAIs followed by the TAE regimen with a 1-month adjustment for a maximum of 3 months. Our TAE regimen allowed us to shorten and extend the treatment intervals even after a 3-month or 1-month treatment interval, or both, were reached. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), and subfoveal choroidal thickness (SCT) were analyzed. MAIN OUTCOME MEASURES: The mean changes in the BCVA, CRT, and SCT from the baseline to 2 years after initiating the treatment were determined. In addition, the number of injections also was determined. RESULTS: The mean BCVA significantly improved from 0.27 logarithm of the minimum angle of resolution (logMAR) units to 0.14 logMAR at 2 years (P < 0.01). The mean CRT decreased significantly from 307±132 μm to 202±76 μm at 2 years (P < 0.01). The mean SCT decreased significantly from 247±106 μm to 203±96 μm at 2 years (P < 0.01). Seventy eyes (72.2%) showed a dry macula at 2 years. The treatment interval at 2 years was 1 month in 20 eyes (20.6%), 2 months in 18 eyes (18.6%), and 3 months in 59 eyes (60.8%). In 49 (50.5%) eyes with a 3-month treatment interval immediately after the loading phase, no fluid was seen in 25 eyes (51.0%) for the duration of this study. The rest had switched to a more frequent scheme. The mean number of injections during the 2-year period was 13.0±3.9. CONCLUSIONS: Intravitreal aflibercept injections with a 1-month adjusted TAE regimen significantly improved the BCVA and CRT with a reduced number of injections at 2 years. The treatment interval was adjusted to extend to 3 months in 60% and to shorten to 1 month in 20% of the eyes at 2 years.

  • Scleral Thickness in Central Serous Chorioretinopathy.

    Imanaga N, Terao N, Nakamine S, Tamashiro T, Wakugawa S, Sawaguchi K, Koizumi H

    Ophthalmology. Retina ( Ophthalmology Retina )  5 ( 3 ) 285 - 291   2020年07月 [ 査読有り ]

    掲載種別: 研究論文(学術雑誌)

     概要を見る

    PURPOSE: To evaluate scleral thickness in central serous chorioretinopathy (CSC) using anterior segment (AS) OCT. DESIGN: Retrospective, comparative study. PARTICIPANTS: Forty-seven eyes of 40 patients with CSC and 53 eyes of 47 age- and gender-matched normal control participants. METHODS: Spherical equivalent, axial length, subfoveal choroidal thickness, and scleral thickness were compared between the CSC and control groups. Scleral thickness was measured by AS OCT 6 mm posterior to the scleral spur in 4 directions. MAIN OUTCOME MEASURE: Scleral thickness in CSC eyes. RESULTS: No differences were found between the 2 groups in age, gender, spherical equivalent, or axial length. Subfoveal choroidal thickness was significantly greater in CSC eyes than in normal control eyes (424.0 ± 101.4 μm vs. 324.3 ± 91.8 μm; P < 0.001). Scleral thickness was significantly greater in CSC eyes than in normal control eyes at the superior (429.4 ± 50.3 μm vs. 395.2 ± 55.4 μm; P = 0.005), temporal (447.7 ± 45.7 μm vs. 396.5 ± 64.1 μm; P < 0.001), inferior (455.7 ± 81.2 μm vs. 437.8 ± 46.9 μm; P = 0.022), and nasal (454.9 ± 44.7 μm vs. 416.6 ± 51.2 μm; P = 0.001) points. CONCLUSIONS: Scleral thickness measured by AS OCT was significantly greater in CSC eyes than in normal control eyes, although no differences were found in spherical equivalent or axial length. Thick sclera may have a role in the pathogenesis of CSC.

  • Macular atrophy after aflibercept therapy for neovascular age-related macular degeneration: outcomes of Japanese multicenter study.

    Koizumi H, Yamamoto A, Ogasawara M, Maruko I, Hasegawa T, Itagaki K, Sekiryu T, Okada AA, Iida T

    Japanese journal of ophthalmology ( Japanese Journal of Ophthalmology )  64 ( 4 ) 338 - 345   2020年07月 [ 査読有り ]

    掲載種別: 研究論文(学術雑誌)

     概要を見る

    PURPOSE: To evaluate the development and rate of growth in macular atrophy after intravitreal injections of aflibercept (IVAs) for neovascular age-related macular degeneration (AMD) over a 2-year period. STUDY DESIGN: Retrospective, interventional, consecutive case series. METHODS: This study included 94 eyes of 92 patients with treatment-naïve AMD involving the foveal center treated with IVAs at 3 university hospitals in Japan. The patients underwent IVAs bimonthly after 3 initial monthly doses in the first year. The protocol was converted to a treat-and-extend regimen in the second year. The incidence and growth rate of macular atrophy were quantified based on hypoautofluorescence detected by fundus autofluorescence images. Additionally, possible background factors related to the development and rate of growth of macular atrophy were investigated. RESULTS: Of 94 eyes, 39 (41.5%) had typical AMD and 55 (58.5%) had polypoidal choroidal vasculopathy. Ten eyes (10.6%) had macular atrophy at the baseline. Of the remaining 84 eyes, 14 (16.7%) had developed new macular atrophy at 2 years, the square root of the growth rate of atrophy was 0.52 mm/year. In multivariate analyses, a poorer best-corrected visual acuity (P = 0.01) and the presence of intraretinal fluid (P = 0.04) at baseline were found to be the independent predictors for the development of macular atrophy. No factors were found that were significantly related to the growth rate of the macular atrophy. CONCLUSIONS: Our study determined the incidence and rate of growth of macular atrophy after IVAs for neovascular AMD in clinical settings. Eyes with vision reduction and intraretinal fluid at the baseline develop macular atrophy more frequently after IVAs for neovascular AMD.

全件表示 >>

著書 【 表示 / 非表示

  • Choroidal Disorders

    古泉 英貴 ( 担当: 共著 , 担当範囲: Imaging and diagnosis of polypoidal choroidal vasculopathy )

    Academic Press, London  2017年 ( 担当ページ: p.349-370 )

  • Fundus Autofluorescence, 2nd ed

    古泉 英貴 ( 担当: 共著 , 担当範囲: Polypoidal choroidal vasculopathy )

    Wolters Kluwer, Philadelphia  2016年 ( 担当ページ: p.94-99 )

MISC(その他業績・査読無し論文等) 【 表示 / 非表示

  • 【自発蛍光で読み解く 眼底疾患】加齢黄斑変性と眼底自発蛍光

    今永 直也, 古泉 英貴

    眼科グラフィック ( (株)メディカ出版 )  8 ( 5 ) 547 - 559   2019年10月

     

  • 【いちばんやさしいOCTの撮りセツ】疾患別OCT画像の撮り方、見方 まずはこれだけ3疾患 加齢黄斑変性

    冨山 亜季子, 古泉 英貴

    眼科ケア ( (株)メディカ出版 )  21 ( 10 ) 1016 - 1025   2019年10月

     

  • 高齢者糖尿病における糖尿病性網膜症の発症及び悪化要因に関する臨床疫学的後方視解析

    新里 幸子, 中山 良朗, 比嘉 盛丈, 新垣 孝一郎, 島袋 充生, 古泉 英貴, 益崎 裕章

    糖尿病 ( (一社)日本糖尿病学会 )  62 ( 9 ) 611 - 611   2019年09月

     

  • 線維柱帯切開術(眼内法)の予後因子の検討

    新垣 淑邦, 酒井 寛, 力石 洋平, 與那原 理子, 上原 千晶, 古泉 英貴

    日本緑内障学会抄録集 ( 日本緑内障学会 )  30回   138 - 138   2019年09月

     

  • 急性原発閉塞隅角症の網膜血管密度および神経節細胞複合体

    力石 洋平, 酒井 寛, 新垣 淑邦, 與那原 理子, 古泉 英貴

    日本緑内障学会抄録集 ( 日本緑内障学会 )  30回   142 - 142   2019年09月

     

全件表示 >>

学術関係受賞 【 表示 / 非表示

  • Achievement Award

    2019年10月   American Academy of Ophthalmology  

    受賞者: ■■■

科研費獲得情報 【 表示 / 非表示

  • 加齢黄斑変性の病態メカニズム解明~沖縄固有因子からの臨床的・遺伝学的アプローチ~

    基盤研究(C)

    課題番号: 21K09746

    研究期間: 2021年04月  -  2024年03月 

    代表者: 古泉 英貴, 寺尾 信宏 

    直接経費: 2,800,000(円)  間接経費: 3,640,000(円)  金額合計: 840,000(円)

  • 加齢黄斑変性の病態メカニズム解明~沖縄固有因子からの臨床的・遺伝学的アプローチ~

    基盤研究(C)

    課題番号: 21K09746

    研究期間: 2021年04月  -  2024年03月 

    代表者: 古泉 英貴, 寺尾 信宏 

    直接経費: 2,800,000(円)  間接経費: 3,640,000(円)  金額合計: 840,000(円)

  • OCT angiography とLSFGを用いた脈絡膜血流動態メカニズムの解明

    基盤研究(C)

    課題番号: 16K11274

    研究期間: 2016年04月  -  2019年03月 

    代表者: 丸子 一朗, 古泉 英貴, 飯田 知弘, 丸子 留佳, 河合 萌子, 大川 優花, 石丸 侑利子, 横山 達郎, 梯 瑞葉, 橋本 絵莉子 

    直接経費: 2,200,000(円)  間接経費: 2,860,000(円)  金額合計: 660,000(円)

     概要を見る

    通常、光干渉断層計アンギオグラフィ(OCTA)において脈絡膜血流が描出できないが、網膜色素上皮萎縮症例や強度近視眼の一部、コロイデレミアやunilateral acute idiopathic maculopathy(UAIM)などでは描出可能であることを報告した。これらの研究から脈絡膜血流が描出できないのは、網膜色素上皮および脈絡毛細血管板による光遮蔽効果によるものであることが示唆されたた。そこで、これらの光遮蔽効果によるアーチファクトを減算することで、正常眼や脈絡膜肥厚例でもある程度描出を可能とする方法を考案した。

  • OCT angiography とLSFGを用いた脈絡膜血流動態メカニズムの解明

    基盤研究(C)

    課題番号: 16K11274

    研究期間: 2016年04月  -  2019年03月 

    代表者: 丸子 一朗, 古泉 英貴, 飯田 知弘, 丸子 留佳, 河合 萌子, 大川 優花, 石丸 侑利子, 横山 達郎, 梯 瑞葉, 橋本 絵莉子 

    直接経費: 2,200,000(円)  間接経費: 2,860,000(円)  金額合計: 660,000(円)

     概要を見る

    通常、光干渉断層計アンギオグラフィ(OCTA)において脈絡膜血流が描出できないが、網膜色素上皮萎縮症例や強度近視眼の一部、コロイデレミアやunilateral acute idiopathic maculopathy(UAIM)などでは描出可能であることを報告した。これらの研究から脈絡膜血流が描出できないのは、網膜色素上皮および脈絡毛細血管板による光遮蔽効果によるものであることが示唆されたた。そこで、これらの光遮蔽効果によるアーチファクトを減算することで、正常眼や脈絡膜肥厚例でもある程度描出を可能とする方法を考案した。

  • 光感受性物質由来蛍光の可視化を応用した加齢黄斑変性の個別化医療の確立

    基盤研究(C)

    課題番号: 15K10850

    研究期間: 2015年04月  -  2018年03月 

    代表者: 飯田 知弘, 丸子 一朗, 古泉 英貴 

    直接経費: 3,600,000(円)  間接経費: 4,680,000(円)  金額合計: 1,080,000(円)

     概要を見る

    滲出型加齢黄斑変性の個別化医療を目指して、光線力学的療法で用いられるベルテポルフィン由来の蛍光を生体眼の眼底から検出可能であるかを検索した。眼底カメラにより、マウス眼では正常眼で網膜血管内に蛍光が観察でき、実験的に作成した脈絡膜新生血管にもベルテポルフィンの集積した蛍光が観察できた。しかし、滲出型加齢黄斑変性症例での撮影では、観察に十分な蛍光を検出することができなかった。

全件表示 >>